RE:RE:Off Label Indications - Ethan Thomas post reminder Cash at the end of Q2 was $14.3 M + $50 M net from the Cantor equity raise = $64M + $23M from SRAM and $8-9M in H2 from sales of product = ($95 - $96M) if you take out $10M / month for July, August and September ($30M) this gives you $65M or roughly 7 months and even if you take out the SRAM money ($23M) you still have $42M approx.. or 4.5 months.
I have spoken directly to Senior management and they have virtually no concern about the SRAM money, nowhere near the hysteria being created here.
The team has 7 months of cash, and in that time they will almost surely have 4050 FDA IND approval, FDA Pg approval, A marketable Pediatric Voucher, other Orphan drug indications, filing for IVIG, MOA pier review and a broad expansion of the reality of the off label Pg uses
I generally accept and live by the addage that the market is truth, but it also dependably overshoots meaningfully in both directions as sentiment swings wildly...but at the end of the days its a forward looking mechanism... and the reality of just how good this situation is in the process of truly being discovered by big US firms and money...and patience will pay despite all this noise